Brought to you by 
Syndax and AZ perform solid tumor combo trial
22 Oct 2021
Executive Summary
Syndax Pharmaceuticals Inc. agreed to pair its monoclonal antibody SNDX6352 with AstraZeneca PLC’s anti-PD-L1 antibody durvalumab in Phase Ib/II trials for solid tumors.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Trial Collaborations
- R&D (No Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Syndax and AZ perform solid tumor combo trial
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice